Tacere Reacquires Asian Rights to Novel Hepatitis C Treatment

Tacere Therapeutics of California said it reacquired Asian rights to its RNA interference candidates for hepatitis C infection from Oncolys BioPharma in Japan. Tacere announced the move immediately after Pfizer exercised its option to continue R&D of the company’s RNAi hepatitis drugs for ex-Asian markets. More details.... Stock Symbol: (NYSE: PFE)